

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 1, 2023

**Consolidated Financial Summary
for the First Six Months of the Fiscal Year Ending March 31, 2024
(Under Japanese GAAP)**

Listed Company: Zeria Pharmaceutical Co., Ltd.

(Stock Exchange: Tokyo Stock Exchange)

Code Number: 4559

(URL: <https://www.zeria.co.jp/>)

Representative: Mitsuhiro Ibe, Representative Director, President & COO

Person in charge of reference: Tomoyuki Nishizawa, Director, Public Relations Division

TEL (03) 3661-1039

Scheduled date to submit the Quarterly Securities Report: November 6, 2023

Scheduled date to commence dividend payments: December 1, 2023

Preparation of supplementary documents to the quarterly financial results: Yes

Holding of quarterly financial results presentation: Yes (for analysts, institutional investors and the press)

(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2023 through September 30, 2023)

(1) Consolidated Financial Results (cumulative)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Six months ended								
September 30, 2023	36,678	8.8	5,327	(9.6)	5,495	6.1	5,396	35.0
September 30, 2022	33,712	17.9	5,894	120.6	5,182	66.3	3,998	89.0

Note: Comprehensive income: For the six months ended September 30, 2023: 11,254 million yen [39.5%]

For the six months ended September 30, 2022: 8,069 million yen [267.7%]

	Basic earnings per share	Diluted earnings per share
Six months ended	Yen	Yen
September 30, 2023	122.43	–
September 30, 2022	90.41	–

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
As of	Million yen	Million yen	%	Yen
September 30, 2023	148,158	75,962	51.1	1,717.40
March 31, 2023	135,034	65,680	48.5	1,484.79

Reference: Equity: As of September 30, 2023: 75,703 million yen

As of March 31, 2023: 65,449 million yen

2. Dividends

	Annual dividends				
	First quarter	Second quarter	Third quarter	Year-end	Total
Year ended	Yen	Yen	Yen	Yen	Yen
March 31, 2023	–	18.00	–	22.00	40.00
Year ending	–	22.00			
March 31, 2024					
Year ending			–	22.00	44.00
March 31, 2024 (Forecast)					

Note: Revision of the forecast of dividends most recently announced: None

3. Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024 (April 1, 2023 through March 31, 2024)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	73,000	6.8	9,100	0.9	9,000	18.7	7,000	13.0	158.80

Note: Revision of the financial forecast most recently announced: None

* Notes

(1) Changes in significant subsidiaries during the six months ended September 30, 2023 (changes in specified subsidiaries resulting in changes in scope of consolidation): None

Inclusion: – (Company name: –) Exclusion: – (Company name: –)

(2) Application of special accounting for preparing the quarterly consolidated financial statements: Yes

(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections

1) Changes in accounting policies due to revisions to accounting standards and other regulations: None

2) Changes in accounting policies due to other reasons: None

3) Changes in accounting estimates: None

4) Restatement of prior period financial statements after error corrections: None

(4) Number of shares issued (common shares)

1) Number of shares issued as of the end of the term (including treasury shares):

As of September 30, 2023: 53,119,190 shares As of March 31, 2023: 53,119,190 shares

2) Number of shares of treasury shares as of the end of the term:

As of September 30, 2023: 9,039,119 shares As of March 31, 2023: 9,038,982 shares

3) Average number of shares during the period (cumulative from the beginning of the fiscal year):

For the six months ended September 30, 2023: 44,080,153 shares

For the six months ended September 30, 2022: 44,229,546 shares

* Quarterly Financial Summary Is Exempt from Quarterly Review Conducted by Certified Public Accountants or An Audit Corporation.

* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters

The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors.